NCT03624543

CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

A Phase II Study of CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: Canadian Cancer Trials Group · Network
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of the disease and relieve some symptoms of cancer. Patients will have already had at least one chemotherapy treatment for their disease at this stage.

Detailed description

CFI-400945 is a new type of drug for breast cancer. Laboratory tests show that it works by blocking a specific protein called Polo-like Kinase 4 (PLK4) that is involved in cancer cell growth. CFI-400945 may slow down the growth of cancer cells or may cause cancer cells to die. This drug has been shown to shrink tumours in animals and has been studied in some patients and appears well tolerated with little side effects. CFI-400945 seems promising but it is not clear if it can offer better results than standard therapy.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	CFI-400945	32mg; 28 day cycles; Cycle 1: Days 1-7 then 15-21 Cycle 2 onward: Daily

Timeline

• Start date: 2019-02-14
• Primary completion: 2026-06-30
• Completion: 2026-12-31
• First posted: 2018-08-10
• Last updated: 2026-01-30

Locations

6 sites across 1 country: Canada